Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shebli ATRASH, Philippe THOMPSON-LEDUC, Ming-Hui TAI, Shuchita KAILA, Kathleen GRAY, Isabelle GHELERTER, Marie-Hélène LAFEUILLE, Patrick LEFEBVRE, Adriana ROSSI
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Multiple myeloma Daratumumab Overall response rate Progression-free survival Time to next treatment Drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/713cdab20a1640d499af42c645824563
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:713cdab20a1640d499af42c645824563
record_format	dspace
spelling	oai:doaj.org-article:713cdab20a1640d499af42c6458245632021-11-14T12:30:35ZTreatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study10.1186/s12885-021-08881-71471-2407https://doaj.org/article/713cdab20a1640d499af42c6458245632021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08881-7https://doaj.org/toc/1471-2407Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effectiveness of daratumumab in the real-world setting, particularly in first line (1 L). This study aimed to describe real-world treatment patterns and clinical outcomes among patients initiating daratumumab across different lines of therapy. Methods A retrospective chart review of adult patients with MM initiating daratumumab between November 2015 and March 2021 was conducted at two clinical sites in the United States. De-identified patient-level data were abstracted in an electronic case report form. Patient characteristics and treatment patterns were described. Clinical outcomes including overall response rate (ORR), progression-free survival, and time to next line of therapy were reported using descriptive statistics and stratified by line of therapy (1 L, second line [2 L] or third line or later [3 L+]). A sub-group analysis evaluated treatment patterns and ORR among patients re-treated with daratumumab. Results A total of 299 patients were included in the study (mean age: 68 years; 55% male). Among them, 26 were 1 L patients, 66 were 2 L patients, and 207 were 3 L+ patients; 110 patients (36.8%) received a stem cell transplant prior to daratumumab initiation. The mean duration of follow-up was 10 months among 1 L patients and 19 months among 2 L and 3 L+ patients. Patients who initiated daratumumab in 1 L had a 100% ORR, while those initiating in 2 L and 3 L+ had an ORR of 78.8 and 65.2%, respectively. Among re-treated patients, ORR was 66.7% during the first treatment segment, and 52.9% during the second treatment segment. Kaplan-Meier rates of progression-free survival at 12 months were 89.9, 75.2, and 53.1% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Kaplan-Meier rates of time to next line of therapy at 12 months were 94.1, 73.4, and 50.0% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Conclusions These findings suggest that daratumumab-based regimens are an effective treatment option across all lines of therapy, with highest response rate in 1 L.Shebli ATRASHPhilippe THOMPSON-LEDUCMing-Hui TAIShuchita KAILAKathleen GRAYIsabelle GHELERTERMarie-Hélène LAFEUILLEPatrick LEFEBVREAdriana ROSSIBMCarticleMultiple myelomaDaratumumabOverall response rateProgression-free survivalTime to next treatmentDrug therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multiple myeloma Daratumumab Overall response rate Progression-free survival Time to next treatment Drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Multiple myeloma Daratumumab Overall response rate Progression-free survival Time to next treatment Drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shebli ATRASH Philippe THOMPSON-LEDUC Ming-Hui TAI Shuchita KAILA Kathleen GRAY Isabelle GHELERTER Marie-Hélène LAFEUILLE Patrick LEFEBVRE Adriana ROSSI Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
description	Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effectiveness of daratumumab in the real-world setting, particularly in first line (1 L). This study aimed to describe real-world treatment patterns and clinical outcomes among patients initiating daratumumab across different lines of therapy. Methods A retrospective chart review of adult patients with MM initiating daratumumab between November 2015 and March 2021 was conducted at two clinical sites in the United States. De-identified patient-level data were abstracted in an electronic case report form. Patient characteristics and treatment patterns were described. Clinical outcomes including overall response rate (ORR), progression-free survival, and time to next line of therapy were reported using descriptive statistics and stratified by line of therapy (1 L, second line [2 L] or third line or later [3 L+]). A sub-group analysis evaluated treatment patterns and ORR among patients re-treated with daratumumab. Results A total of 299 patients were included in the study (mean age: 68 years; 55% male). Among them, 26 were 1 L patients, 66 were 2 L patients, and 207 were 3 L+ patients; 110 patients (36.8%) received a stem cell transplant prior to daratumumab initiation. The mean duration of follow-up was 10 months among 1 L patients and 19 months among 2 L and 3 L+ patients. Patients who initiated daratumumab in 1 L had a 100% ORR, while those initiating in 2 L and 3 L+ had an ORR of 78.8 and 65.2%, respectively. Among re-treated patients, ORR was 66.7% during the first treatment segment, and 52.9% during the second treatment segment. Kaplan-Meier rates of progression-free survival at 12 months were 89.9, 75.2, and 53.1% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Kaplan-Meier rates of time to next line of therapy at 12 months were 94.1, 73.4, and 50.0% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Conclusions These findings suggest that daratumumab-based regimens are an effective treatment option across all lines of therapy, with highest response rate in 1 L.
format	article
author	Shebli ATRASH Philippe THOMPSON-LEDUC Ming-Hui TAI Shuchita KAILA Kathleen GRAY Isabelle GHELERTER Marie-Hélène LAFEUILLE Patrick LEFEBVRE Adriana ROSSI
author_facet	Shebli ATRASH Philippe THOMPSON-LEDUC Ming-Hui TAI Shuchita KAILA Kathleen GRAY Isabelle GHELERTER Marie-Hélène LAFEUILLE Patrick LEFEBVRE Adriana ROSSI
author_sort	Shebli ATRASH
title	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
title_short	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
title_full	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
title_fullStr	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
title_full_unstemmed	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
title_sort	treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: a real-world chart review study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/713cdab20a1640d499af42c645824563
work_keys_str_mv	AT shebliatrash treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT philippethompsonleduc treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT minghuitai treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT shuchitakaila treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT kathleengray treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT isabelleghelerter treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT mariehelenelafeuille treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT patricklefebvre treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy AT adrianarossi treatmentpatternsandeffectivenessofpatientswithmultiplemyelomainitiatingdaratumumabacrossdifferentlinesoftherapyarealworldchartreviewstudy
_version_	1718429174110093312

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

Ejemplares similares